CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
| Eaton Vance Dividend Builder Fd Cl C (NASDAQ: CTMX) | Delayed: 2.42 -0.15 (5.84%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.57 | 52 Week High | $24.68 | |||
| Open | $2.56 | 52 Week Low | $9.10 | |||
| Day High | $2.58 | P/E | N/A | |||
| Day Low | $2.41 | EPS | $0.00 | |||
| Volume | 4,000,871 | |||||
